A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis

Status:
Not yet recruiting

Trial end date:
2027-05-01

Target enrollment:

Participant gender:

A Study of the Anti-CD 19 Chimeric Antigen Receptor T Cell Therapy for Subjects with Myasthenia Gravis

Phase 2

Kyverna Therapeutics

Cyclophosphamide
Fludarabine